A new autism study shows that use of the Behavior Intervention Plan (BIP) Builder improves the quality of behavior intervention plans designed by clinicians treating children with autism spectrum disorder (ASD). The study, conducted by the Center for Autism and Related Disorders (CARD), is published in the December 2013 edition of the scientific journal Research [...]
We salute the U.S. Food and Drug Administration (FDA) for increasing consumer awareness of the ineffectiveness of hyperbaric oxygen therapy (HBOT) as a treatment for autism spectrum disorder (ASD). The FDA released a report on Aug. 22, 2013, stating that “HBOT has not been clinically proven to cure or be effective in the treatment of autism, cancer, or diabetes, nor has it been approved by FDA.”
Earlier this month, the new Diagnostic and Statistical Manual of Mental Disorders (DSM-5) was released. This has been highly anticipated by the autism community because the diagnostic criteria for autism spectrum disorder has been changed. Many autism community members – especially those whose children are diagnosed with Asperger syndrome – have expressed concerns about whether their children could lose their diagnosis and, consequently, lose access to treatment.
Card is happy to announce that on February 19th, that we will be teaming up with Lineagen to offer an open house presentation and discussion on the benefits of genetic testing with individuals on the spectrum.
That’s why CARD is proud to be apart of the Autism Research Group (ARG). This research group is led by CARD’s own Director of Research and Development, Dr. Jonathan Tarbox and is dedicated to making a change for the better for those with autism spectrum disorders.
The Center for Autism and Related Disorders (CARD) is the only private, for-profit corporation contributing significantly to autism research in the United States, ranking third among non-governmental organizations contributing to autism research in the United States, according to the 2010 IACC Autism Spectrum Disorder Research Portfolio Analysis Report. The Interagency Autism Coordinating Committee, a federal advisory committee that coordinates all efforts within the Department of Health and Human Services concerning autism spectrum disorder (ASD), released its annual IACC Autism Spectrum Disorder Research Portfolio Analysis Report, which “tracks US inputs or investments into autism research.” CARD’s investment in autism research has increased every year since IACC began tracking autism research funding.
“Our organization does research that matters to families of children with autism and our mission is to share the results with the world. ARG’s research findings will allow more families to access effective treatment,” says ARG Executive Director Jonathan Tarbox, PhD, BCBA-D.